par-3 Antibody

What is PAR-3 and what are its primary biological functions?

PAR-3 (also known as PARD3 - partitioning defective 3 homolog) functions as an adapter protein involved in asymmetrical cell division and cell polarization processes . It plays a central role in the formation of epithelial tight junctions and is essential for establishing and maintaining cellular polarity across different tissue types.

PAR-3 exerts its functions by:

• Forming a cell polarity complex with Par6 and aPKC (atypical protein kinase C)

• Targeting the phosphatase PTEN to cell junctions

• Contributing to Schwann cell peripheral myelination

• Mediating the initial clustering of junction and polarity proteins that subsequently travel and accumulate apically during polarization

• Interacting with GTP-bound Rho small GTPases through the PARD6-PARD3 complex

• Participating in neuronal polarity establishment and normal axon formation

These diverse functions highlight PAR-3's critical role in developmental processes and tissue architecture maintenance.

What types of PAR-3 antibodies are available and how do they differ?

Several types of PAR-3 antibodies are available for research applications, each with distinct characteristics:

Key differences include:

• Epitope specificity: Different antibodies target distinct regions of PAR-3. For example, MAB8030 targets amino acids 451-555 of human PARD3 , while ab191204 targets a region within the C-terminus (aa 1300 to C-terminus)

• Available conjugations: Many antibodies are available in both unconjugated form and conjugated to agarose, HRP, PE, FITC, or Alexa Fluor dyes

• Performance in specific applications: Some antibodies perform better in certain techniques like immunofluorescence versus western blotting

How should PAR-3 antibodies be stored and handled for optimal performance?

Proper storage and handling of PAR-3 antibodies are crucial for maintaining their performance:

Storage conditions:

• Store at -20°C to -70°C for long-term storage (12 months from date of receipt)

• For short-term storage (1 month), refrigerate at 2-8°C under sterile conditions after reconstitution

• For medium-term storage (6 months), store at -20°C to -70°C under sterile conditions after reconstitution

• Aliquot antibodies to avoid repeated freeze-thaw cycles that can degrade antibody quality

Buffer conditions:

• Most antibodies are supplied in PBS, pH 7.3, with 0.02% sodium azide and 50% glycerol

• Working dilutions vary by application:

  • WB: 1/500 - 1/1000

  • IHC: 1/50 - 1/200

  • IF/ICC: 1/50 - 1/500

  • IP: 1/200 - 1/1000

Handling precautions:

• Use manual defrost freezers to prevent damage from automatic defrost cycles

• Always use sterile technique when handling reconstituted antibodies

• Centrifuge briefly before opening vials to collect all material

• Optimal dilutions should be determined empirically for each application

How does PAR-3 contribute to epithelial cell polarization at the molecular level?

PAR-3 plays a sophisticated role in epithelial polarization through several key mechanisms:

Initial polarization events:
PAR-3 facilitates the initial stages of intestinal epithelial cell polarization by colocalizing with HMR-1 (E-cadherin), other adherens junction proteins, and polarity proteins PAR-6 and PKC-3 (aPKC) within cortical foci . These protein clusters then travel apically and aggregate as polarization proceeds, establishing distinct membrane domains.

Junction formation:
In MDCK cells, which serve as a model for epithelial polarization, PAR-3 localizes to tight junctions . When PAR-3 levels are reduced by siRNA treatment, the relocalization of tight junction and other apical proteins is severely delayed following calcium depletion and reintroduction (calcium switch) . This indicates PAR-3's essential role in junction reformation after polarization disruption.

Molecular interactions:
The PARD6-PARD3 complex links GTP-bound Rho small GTPases to atypical protein kinase C proteins , creating a signaling hub that regulates cytoskeletal dynamics and membrane identity. Association with PARD6B may prevent PAR-3's interaction with F11R/JAM1, thereby regulating tight junction assembly .

Structural contributions:
PAR-3 contains multiple protein interaction domains, including three PDZ domains that enable it to scaffold various junction and polarity proteins . The second PDZ domain (present in the region of amino acids 451-555) is particularly important for heterophilic interactions and is conserved across all PAR-3 isoforms .

This orchestrated series of molecular events demonstrates how PAR-3 functions as both an architectural and signaling component in establishing epithelial cell polarity.

What are the critical differences between PAR-3 isoforms and their functional implications?

PAR-3/PARD3 exists in multiple isoforms with significant functional implications:

Isoform diversity:

• At least 10 reported isoforms of PARD3 exist, varying in length from 988 amino acids to 1356 amino acids

• These isoforms appear as distinct bands on western blots, typically at 100 kDa, 150 kDa, and 180 kDa

Domain structure:

• The second PDZ domain (within aa 451-555) is conserved across all isoforms, highlighting its fundamental importance to PAR-3 function

• Different domains of PAR-3 have distinct roles during development , suggesting isoform-specific functions

Domain-specific functions:

• Specific domains mediate interactions with PAR-6, aPKC, and other polarity proteins

• Different phosphorylated forms of PAR-3 can have different roles during C. elegans development

• The varying domain composition of isoforms likely contributes to tissue-specific functions

Experimental considerations:

• When selecting antibodies, researchers must consider which epitopes are present across the isoforms of interest

• The MAB8030 antibody targets amino acids 451-555 (which includes the second PDZ domain) , making it useful for detecting multiple isoforms

• The ab191204 antibody targets the C-terminal region (aa 1300 to C-terminus) , which may not be present in all isoforms

Understanding isoform-specific functions remains an important area of research, particularly for explaining tissue-specific differences in PAR-3 function and localization.

How do PAR-3 phosphorylation states affect its localization and function?

PAR-3 function is regulated through phosphorylation in ways that affect its protein interactions, localization, and activity:

Phosphorylation regulation:

• Different phosphorylated forms of PAR-3 have distinct roles during C. elegans development

• aPKC (atypical protein kinase C) is a key regulator that phosphorylates PAR-3, affecting its binding interactions and localization

Functional implications:

• Phosphorylation can modulate PAR-3's ability to form complexes with PAR-6 and aPKC

• Phosphorylation states affect PAR-3's role in establishing asymmetric cell divisions

• Modified PAR-3 can exhibit altered binding affinity for membrane components and junction proteins

Methodological considerations:

• When studying PAR-3 phosphorylation, phosphatase inhibitors must be included during sample preparation

• Antibodies may have differential affinity for phosphorylated versus non-phosphorylated forms

• Detection of phosphorylated PAR-3 may require phospho-specific antibodies

Experimental approaches:

• Immunoprecipitation followed by phospho-specific western blotting

• Mass spectrometry to identify phosphorylation sites

• Mutation of phosphorylation sites to examine functional consequences

Understanding the complex phosphorylation patterns of PAR-3 provides insight into how this scaffolding protein dynamically responds to cellular signals to coordinate polarization events.

What are the optimal conditions for western blot detection of PAR-3?

Successful western blot detection of PAR-3 requires careful optimization due to its large size and multiple isoforms:

Sample preparation:

• Include protease inhibitors and phosphatase inhibitors to prevent degradation and preserve phosphorylation states

• Use fresh samples whenever possible to minimize degradation

• Consider using RIPA buffer with 1-2% SDS for complete solubilization of membrane-associated PAR-3

Gel electrophoresis:

• Use low percentage gels (6-8%) or gradient gels (4-15%) to properly resolve the large PAR-3 isoforms

• Expected molecular weights: multiple isoforms at approximately 100 kDa, 150 kDa, and 180 kDa

Transfer conditions:

• Use wet transfer for optimal results with large proteins

• Consider extended transfer times at lower voltages for complete transfer of high molecular weight proteins

Blocking and antibody incubation:

• Recommended dilutions for primary antibodies:

  • PAR-3 Antibody (8E8): 1/500 - 1/1000

  • PAR-3 Antibody (G-4): 1/500 - 1/1000

  • PARD3 polyclonal antibody: 1/500 - 1/1000

• Incubate primary antibody overnight at 4°C with gentle agitation

• Use appropriate secondary antibodies at manufacturer-recommended dilutions

Detection systems:

• Enhanced chemiluminescence (ECL) or fluorescence-based detection systems are suitable

• Longer exposure times may be necessary to detect lower abundance isoforms

Controls:

• Include positive control lysates from cells known to express PAR-3

• Consider using PAR-3 knockdown or knockout samples as negative controls

How should immunofluorescence experiments be optimized for PAR-3 detection?

Optimizing immunofluorescence for PAR-3 detection requires attention to several key parameters:

Fixation methods:

• Methanol fixation has been successfully used for PAR-3 antibodies in C. elegans studies

• For mammalian cells, 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100 may be preferred

• Compare multiple fixation protocols to identify optimal conditions for your specific antibody and cell type

Antibody dilutions:

• For mouse monoclonal antibodies (P1A5, P4A1): 1:70 dilution has been effective

• For polyclonal antibodies: typically 1:50 - 1:500

• Optimal dilutions should be determined empirically for each application and cell type

Detection strategies:

• Secondary antibodies: Alexa Fluor 488, Cy3, or other fluorophore-conjugated antibodies at 1:200-1:400 dilution

• Pre-conjugated primary antibodies (e.g., FITC or PE conjugates) can reduce background and simplify protocols

Visualization systems:

• PAR-3 has been successfully visualized in HEK293 cells using NorthernLights™ 557-conjugated secondary antibody

• DAPI counterstaining helps visualize nuclei in relation to PAR-3 localization

• Co-staining with junction markers (E-cadherin, ZO-1) can provide contextual information

Expected localization patterns:

• In epithelial cells: PAR-3 typically localizes to tight junctions

• In polarizing cells: May appear in cortical foci that travel apically

• In HEK293 cells: Specific staining localized to plasma membrane

An example of successful PAR-3 immunofluorescence is documented with the PARD3/Par3 antibody (MAB8030) in HEK293 cells, where specific staining was localized to the plasma membrane when counterstained with DAPI .

What are the best practices for immunoprecipitation of PAR-3 and its binding partners?

Immunoprecipitation (IP) of PAR-3 requires careful optimization to preserve protein-protein interactions:

Antibody selection:

• Various PAR-3 antibodies are validated for IP, including:

  • PAR-3 Antibody (8E8)

  • PAR-3 Antibody (G-4)

  • PARD3 polyclonal antibody (recommended dilution: 1/200 - 1/1000)

IP formats:

• Traditional IP using unconjugated antibodies with Protein A/G beads

• Direct IP using antibodies pre-conjugated to agarose, such as PAR-3 Antibody (8E8) AC

Co-immunoprecipitation considerations:

• Gentle lysis conditions are crucial for preserving interactions with binding partners

• Low-stringency wash buffers help maintain protein complexes

• Include protease and phosphatase inhibitors to prevent degradation

Studying PAR complex components:
When investigating PAR-3's interactions with PAR-6 and PKC-3:

• Co-staining experiments using anti-PAR-3 mouse monoclonal, anti-PAR-6 rabbit polyclonal, and anti-PKC-3 rat polyclonal antibodies have been successful

• Different PAR-3 domains interact with different partners; consider which domains are recognized by your IP antibody

Validation strategies:

• Reciprocal IPs (pulling down with partner protein antibodies)

• Western blot analysis of IP products using antibodies against expected interaction partners

• Include appropriate controls (IgG control, PAR-3 depleted lysate)

Expected binding partners:
Based on the literature, successful IPs should detect interactions with:

• PAR-6 and PKC-3 (aPKC)

• Components of tight junctions and adherens junctions

• PTEN in polarized epithelia

• Rho small GTPases via the PARD6-PARD3 complex

Why might I observe inconsistent PAR-3 immunostaining patterns across different tissues?

Inconsistent PAR-3 immunostaining patterns across tissues can result from several biological and technical factors:

Biological factors:

• Isoform expression: Different tissues express different PAR-3 isoforms , affecting epitope availability

• Developmental stage: PAR-3 localization changes dynamically during polarization processes

• Cell type-specific functions: PAR-3 localizes to tight junctions in epithelial cells but may have different distributions in other cell types

• Interaction partners: Association with different binding partners can mask antibody epitopes

• Phosphorylation status: Different phosphorylated forms of PAR-3 have distinct roles and may affect antibody recognition

Technical considerations:

• Epitope specificity: Different antibodies recognize different regions of PAR-3:

  • MAB8030 targets amino acids 451-555 (second PDZ domain)

  • ab191204 targets the C-terminal region (aa 1300 to C-terminus)

• Fixation sensitivity: Some epitopes are better preserved by specific fixation methods:

  • Methanol fixation has been successful in C. elegans studies

  • Paraformaldehyde fixation may be preferred for certain applications

• Antibody reactivity: Confirm that your antibody recognizes your species of interest:

  • Some antibodies show reactivity to human, mouse, and rat PAR-3

  • Others may have more limited species reactivity

Validation approaches:

• Use multiple antibodies that recognize different epitopes of PAR-3

• Include PAR-3 knockout or knockdown controls to confirm specificity

• Co-stain with known PAR-3 binding partners (PAR-6, aPKC) to verify localization patterns

• Compare your results with published localization data for your tissue of interest

How should I interpret multiple bands in PAR-3 western blots?

Multiple bands in PAR-3 western blots are common and can provide valuable biological information:

Expected PAR-3 banding pattern:

• Multiple isoforms typically appear at approximately 100 kDa, 150 kDa, and 180 kDa

• PARD3 exists in at least 10 reported isoforms ranging from 988 aa to 1356 aa

Sources of multiple bands:

• Isoform diversity: Different isoforms due to alternative splicing

• Post-translational modifications: Phosphorylation and other modifications alter mobility

• Proteolytic processing: PAR-3 may undergo regulated proteolytic processing

• Cross-reactivity: Some antibodies may detect related proteins like PARD3B/Par3b

  • MAB8030 shows 100% cross-reactivity with recombinant human PARD3b/Par3b in ELISAs

Verification strategies:

• Compare with positive control samples known to express PAR-3

• Use isoform-specific antibodies or antibodies targeting different regions

• Perform additional validation using mass spectrometry

• Compare expression patterns across multiple cell types or tissues

Interpreting tissue-specific patterns:

• Different tissues may express distinct isoform repertoires

• The relative intensity of bands may reflect tissue-specific expression levels

• Changes in banding patterns during development or in disease states may have biological significance

Understanding the complex PAR-3 banding pattern is essential for accurate data interpretation and can provide insights into tissue-specific PAR-3 regulation and function.

What controls should be included in PAR-3 antibody experiments to ensure reliability?

Robust controls are essential for ensuring reliable PAR-3 antibody data:

Positive controls:

• Cell lines known to express PAR-3 (HEK293 cells have been validated)

• Tissues with established PAR-3 expression patterns

• Recombinant PAR-3 protein for antibody validation

• Overexpression systems with tagged PAR-3 constructs

Negative controls:

• Primary antibody omission to assess secondary antibody specificity

• Isotype controls matching the primary antibody class

• PAR-3 knockdown or knockout samples using siRNA or CRISPR/Cas9

• Peptide competition assays to confirm antibody specificity

Specificity controls:

• Testing for cross-reactivity with related proteins:

  • MAB8030 shows 100% cross-reactivity with recombinant human PARD3b/Par3b in ELISAs

• Using multiple antibodies targeting different epitopes:

  • In co-staining experiments, anti-PAR-3 monoclonal antibodies P1A5 and P4A1 showed largely overlapping patterns

Application-specific controls:

• For western blot: Molecular weight markers, loading controls

• For immunofluorescence: Co-staining with known markers (PAR-6, aPKC)

• For immunoprecipitation: IgG control, input lysate control

• For flow cytometry: Unstained and single-color controls

Documentation and validation:

• Document antibody catalog numbers, lot numbers, and dilutions

• Validate new antibody lots before use in critical experiments

• Consider confirming key findings with complementary techniques

Implementing these controls ensures experimental reliability and facilitates accurate interpretation of PAR-3 antibody data across different experimental contexts.

How can PAR-3 antibodies be used to study neuronal development and polarization?

PAR-3 antibodies offer valuable tools for investigating neuronal development and polarization:

Neuronal applications:

• PAR-3 is required for establishing neuronal polarity and normal axon formation in cultured hippocampal neurons

• Antibodies can help visualize the subcellular localization of PAR-3 during axon specification

• Immunoprecipitation can identify neuron-specific PAR-3 binding partners

Methodological approaches:

• Time-course immunofluorescence to track PAR-3 localization during neuronal differentiation

• Co-immunoprecipitation to identify stage-specific protein interactions

• Combining PAR-3 antibody staining with live-cell imaging of fluorescently tagged proteins

Specific research questions:

• How does PAR-3 localization change during axon specification?

• Which PAR-3 domains are essential for neuronal polarity?

• How do PAR-3 interactions differ between neurons and epithelial cells?

• What is the relationship between PAR-3 and cytoskeletal dynamics in growth cones?

Technical considerations:

• Selection of appropriate neuronal culture systems

• Optimization of fixation methods for neuronal structures

• Co-staining with neuronal markers and cytoskeletal components

This research direction could significantly enhance our understanding of the molecular mechanisms governing neuronal polarity establishment, which is fundamental to brain development and function.

What are the latest methodological advances in studying PAR-3 dynamics?

Recent methodological advances have expanded the toolkit for studying PAR-3 dynamics:

Live imaging approaches:

• Live imaging has been used to establish that PAR-3 is required for the formation of HMR-1 (E-cadherin) GFP foci as intestinal epithelial cells polarize

• Fluorescently tagged PAR-3 constructs enable real-time visualization of protein dynamics

• FRAP (Fluorescence Recovery After Photobleaching) analysis can reveal PAR-3 mobility within cellular structures

Advanced microscopy techniques:

• Super-resolution microscopy provides nanoscale visualization of PAR-3 organization

• Structured illumination microscopy (SIM) and STORM offer improved resolution over conventional confocal microscopy

• Single-molecule tracking reveals the dynamics of individual PAR-3 molecules

Proximity labeling methods:

• BioID or APEX2 fusion proteins can identify proteins in close proximity to PAR-3 in living cells

• These approaches complement traditional co-immunoprecipitation by identifying transient or weak interactions

Quantitative analysis:

• Automated image analysis software can quantify PAR-3 clustering and colocalization with binding partners

• Computational modeling of PAR-3 dynamics provides insights into polarization mechanisms

CRISPR-based approaches:

• Endogenous tagging of PAR-3 with fluorescent proteins or epitope tags

• Domain-specific mutations to dissect functional requirements

• Optogenetic control of PAR-3 interactions

These methodological advances promise to provide unprecedented insights into PAR-3 function across different cellular contexts and developmental stages.